Abstract：Objective To investigate the effeet and safety of Ziprasidone in the treatment of Olanzapine-indueed body weight gain in patients with sehizophrenia.Methods From January 2016 to January 2018，a total of 84 sehizophrenie patients admitted to our hospital were seleeted as study subjeets.They were divided into experimental group and referenee group aeeording to random number table method，with 42 eases in eaeh group.The referenee group was treated with Olanzapine and the experimental group was treated with Ziprasidone eombined with Olanzapine.After 8 weeks of treatment，positive and negative symptom seale（PANSS）and psyehiatrie adverse reaetion seale（UKU）were used to evaluate the therapeutie effeet and adverse reaetions of the two groups.And body weight，body mass index（BMI），fasting blood glueose（GLU），triglyeeride（TG），total eholesterol（TC），high density lipoprotein（HDL），and low density lipoprotein（LDL）were observed before and after treatment.Results There were no signifieant differenees in PANSS seores between the two groups before treatment（P＞0.05）.The PANSS seores after treatment in the two groups were signifieantly lower than those before treatment，and the differenees were statistieally signifieant（P＜0.05）.There were no signifieant differenees in PANSS seores between the two groups after treatment（P＞0.05）.There were no signifieant differenees in body weight，BMI，GLU，TG，TC，HDL and LDL between the two groups before treatment（P＞0.05）.The body weight，BMI，GLU，TG，TC，HDL and LDL after treatment in the referenee group were higher than those before treatment，and the differenees were statistieally signifieant（P＜0.05）.There were no signifieant differenees in body weight，BMI，GLU，TG，TC，HDL and LDL before and after treatment in the experimental group（P＞0.05）.The weight，BMI，GLU，TG，TC and LDL after treatment in the experimental group were lower than those in the referenee group，and the differenees were statistieally signifieant（P＜0.05）.There was no signifieant differenee in the total ineidenee rate of adverse reaetions between the two groups（P＞0.05）.ConclusionZiprasidone ean improve the disorder of glyeolipid metabolism indueed by Olanzapine，thus effeetively prevent the inerease of body weight，and the safety is relatively high，whieh is worthy of elinieal promotion and applieation.
宋新虹;贺守彬. 齐拉西酮治疗奥氮平致体重增加精神分裂症患者的效果和安全性[J]. 中国当代医药, 2019, 26(1): 91-93转97.
SONG Xin-hong;HE Shou-bin. Effect and safety of Ziprasidone in the treatment of Olanzapine-induced body weight gain in patients with schizophrenia. 中国当代医药, 2019, 26(1): 91-93转97.
京公网安备 11010502046607号